Drawing for ALUVIA

USPTO serial 88356352

ALUVIA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
NOVAKOVIC, MIROSLAV
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ALUVIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Matthew O. Brady

Matthew O. Brady AbbVie Inc.18655 Teller AvenueIrvine, CA 92612UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations, namely, antiviralsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 17, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 17, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 16, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 15, 2022EX5GSOU EXTENSION 5 GRANTED—
Mar 15, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 4, 2022EXT5SOU EXTENSION 5 FILED—
Mar 4, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 2, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 2, 2022EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Mar 2, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 2, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 24, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 22, 2021EX4GSOU EXTENSION 4 GRANTED—
Jul 22, 2021EXT4SOU EXTENSION 4 FILED—
Jul 22, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 6, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 4, 2021EX3GSOU EXTENSION 3 GRANTED—
Mar 4, 2021EXT3SOU EXTENSION 3 FILED—
Mar 4, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 3, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 1, 2020EX2GSOU EXTENSION 2 GRANTED—
Sep 1, 2020EXT2SOU EXTENSION 2 FILED—
Sep 1, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 29, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 19, 2020EX1GSOU EXTENSION 1 GRANTED—
Feb 19, 2020EXT1SOU EXTENSION 1 FILED—
Feb 19, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 19, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 19, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 19, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 10, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 16, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 16, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 26, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 12, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 6, 2019DOCKASSIGNED TO EXAMINER—
Apr 18, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 29, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance